DDInter1014 DDInter1676
Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. It was granted approval by Health Canada in September 2010.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lacosamide {u} (Compound) resembles {v} (Compound) Lisdexamfetamine
Lacosamide {u} (Compound) resembles {v} (Compound) Bethanidine
Lacosamide {u} (Compound) treats {v} (Disease) epilepsy syndrome
Lacosamide {u} (Compound) binds {v} (Gene) SCN10A
Lacosamide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Lacosamide {u} (Compound) causes {v} (Side Effect) Liver function test abnormal
Lacosamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Lacosamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Lacosamide {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Lacosamide (Compound) resembles Lisdexamfetamine (Compound)
Lacosamide (Compound) resembles Bethanidine (Compound)
Lacosamide (Compound) treats epilepsy syndrome (Disease)
Lacosamide (Compound) binds SCN10A (Gene)
Lacosamide (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Lacosamide (Compound) causes Liver function test abnormal (Side Effect)
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Lacosamide may lead to a major life threatening interaction when taken with Dolasetron